DSM introduces green tech-processed API to China
Shanghai. December 10. INTERFAX-CHINA - DSM China Ltd. has signed long term supply contracts with two Chinese drug markers for a patented green technology-processed active pharmaceutical ingredient (API), it announced on Dec. 9.
According to the announcement, Guangzhou Baiyunshan Pharmaceutical Co. Ltd. and Shandong Xinhua Pharmaceutical Co. Ltd. will purchase Dutch pharmaceutical giant DSM's Pure Actives cefalexin API for use in the production of cefalexin capsules, a type of cephalosporin antibiotic. "This marks the first time that DSM is introducing its Pure Actives product series in China, which will allow Baiyunshan Pharma and Xinhua Pharma to produce drugs in a more environmentally friendly way," Zhao Hongmei, a manager in DSM China's anti-infective drugs department, told Interfax on Dec. 10.
"The use of DSM's Pure Actives cefalexin API can help manufacturers cut solvent and chemical wastes by 90 percent," Shi Lina, a corporate communications manager with DSM China, told Interfax.
Baiyunshan Pharma's general manager Chen Mao was quoted as saying in the announcement that the company is adopting green technology in its drug manufacturing process so as to develop more sustainably even though production costs are expected to rise by 30 percent.